Regulus Therapeutics Inc. RGLS
8.16 0.00 (+0.00%)
At closeJun 25, 2025, 4:00 PM EDT
8.16 Day range 8.16
52-week range unavailable
- YTD
- +416.46%
- 1 year
- +298.05%
News
https://www.marketscreener.com Novartis AGcompleted the acquisition of Regulus Therapeutics Inc.. Novartis AG (SWX:NOVN) submitted a written non-binding indication of interest to acquire Regulus Therapeutics Inc. (NasdaqCM:RGLS) for approximately $200 million on April 4, 2025. Novartis AG…
globenewswire.com Novartis completes acquisition of Regulus Therapeutics Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common…
globenewswire.com Novartis announces commencement of tender offer to acquire Regulus Therapeutics Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to…
prnewswire.com Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right ("CVR") upon the…
businesswire.com REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
prnewswire.com SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS NEW YORK , April 30, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024…
benzinga.com Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.
benzinga.com Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
businesswire.com RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus…
businesswire.com Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to…
reuters.com Novartis to buy Regulus Therapeutics for up to $1.7 billion Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
globenewswire.com Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage…
prnewswire.com Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to…
zacks.com Should You Buy Regulus (RGLS) After Golden Cross? Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out…
prnewswire.com Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit SAN DIEGO , April 2, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease Regulus Therapeutics Inc. RGLS released topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen (RGLS8429) autosomal dominant polycystic kidney disease (ADPKD)…
prnewswire.com Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Positive Topline Data from the Fourth Cohort of Patients Consistent demonstration of polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to achieve optimal kidney exposure…
247wallst.com 4 Best Stocks To Buy Under $5 If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention.
zacks.com What Makes Regulus (RGLS) a New Buy Stock Regulus (RGLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
prnewswire.com Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates Positive topline results from an interim analysis of the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of farabursen (RGLS8429) for the treatment of autosomal…
benzinga.com Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
benzinga.com Gold Down Over 1%; ClearOne Shares Spike Higher U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also…
benzinga.com Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.
benzinga.com Nasdaq Surges Over 1%; Blade Air Mobility Shares Plummet U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Tuesday. The Dow traded up 0.48% to 38,955.84 while the NASDAQ rose 1.12% to 16,198.58. The S&P 500…
benzinga.com Dow Gains 100 Points; US Inflation Rate Rises To 3.2% In February U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.27% to 38,873.55 while the NASDAQ…- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 198 companies hit new 52-week lows.
benzinga.com Earnings Scheduled For March 9, 2023 Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.- benzinga.com Earnings Scheduled For November 10, 2022 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.
- benzinga.com Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
- benzinga.com Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
- benzinga.com Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday's Mid-Day Session Gainers HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist…
- benzinga.com Earnings Scheduled For August 11, 2022 Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
benzinga.com 110 Biggest Movers From Friday Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.- benzinga.com 56 Stocks Moving In Friday's Mid-Day Session Gainers Veru Inc. (NASDAQ: VERU) shares jumped 62.5% to $14.67 after the company reported quarterly results on Thursday. Jefferies maintained Veru with a Buy and raised the price target from $33 to…
- benzinga.com Earnings Scheduled For May 12, 2022 Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.
- benzinga.com 99 Biggest Movers From Yesterday Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 435 companies set new 52-week lows.- benzinga.com Earnings Scheduled For March 10, 2022 Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million.
- benzinga.com 68 Biggest Movers From Yesterday Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
- benzinga.com Stocks Hitting New 52-Week Lows Today On Monday morning, 60 companies achieved new lows for the year.
- benzinga.com Earnings Scheduled For November 10, 2021 Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
benzinga.com 50 Biggest Movers From Yesterday Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price…- benzinga.com 39 Stocks Moving In Wednesday's Mid-Day Session Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target.
- benzinga.com 20 Stocks Moving in Wednesday's Pre-Market Session Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday.
- benzinga.com Earnings Scheduled For May 13, 2021 Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday This morning 194 companies reached new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday, 596 companies set new 52-week highs.